1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. SICKLE CELL DISEASE TREATMENT MARKET BY TREATMENT
5.1. Introduction
5.2. Blood Transfusion
5.3. Pharmacotherapy
5.4. Bone Marrow Transplant
6. SICKLE CELL DISEASE TREATMENT MARKET BY END-USER
6.1. Introduction
6.2. Hospitals
6.3. Diagnostic Centers
6.4. Others
7. SICKLE CELL DISEASE TREATMENT MARKET BY GEOGRAPHY
7.1. Introduction
7.2. North America
7.2.1. USA
7.2.2. Canada
7.2.3. Mexico
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Others
7.4. Europe
7.4.1. Germany
7.4.2. France
7.4.3. United Kingdom
7.4.4. Spain
7.4.5. Others
7.5. Middle East and Africa
7.5.1. Saudi Arabia
7.5.2. UAE
7.5.3. Others
7.6. Asia Pacific
7.6.1. China
7.6.2. India
7.6.3. Japan
7.6.4. South Korea
7.6.5. Indonesia
7.6.6. Thailand
7.6.7. Others
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Major Players and Strategy Analysis
8.2. Market Share Analysis
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Competitive Dashboard
9. COMPANY PROFILES
9.1. Novartis AG
9.2. Bluebird bio, Inc.
9.3. Agios Pharmaceuticals, Inc.
9.4. Pfizer Inc.
9.5. Emmaus Medical, Inc.
9.6. Bristol-Myers Squibb Company
9.7. Addmedica
9.8. Modus Therapeutics AB
9.9. Crispr Therapeutics
9.10. Sancilio Pharmaceuticals Company, Inc.
10. APPENDIX
10.1. Currency
10.2. Assumptions
10.3. Base and Forecast Years Timeline
10.4. Key benefits for the stakeholders
10.5. Research Methodology
10.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES